Mucormycosis Market Share, Size, Trends, Industry Analysis Report; By Diagnosis (Computed Tomography, MRI, Tissue Biopsy); By Treatment (Surgery, Antifungal Drugs, Amphotericin B Therapy, Others); By End-Use; By Region; Segment Forecast, 2021 - 2028

报告摘要

The global mucormycosis market was valued at USD 422.7 million in 2020 and is expected to grow at a CAGR of 3.4% during the forecast period. The upsurge in the prevalence of fungal infections, the availability of an extensive variety of drugs, the rising incidence of immunological diseases, and the emergence of coronavirus are some of the factors driving the market growth. Furthermore, rising public awareness of fungal infection and increased government funding for research and development has further fueled the market growth.

了解有关此报告的更多信息：request for sample pages

全球黏膜型市场将主要推动在预测期间Covid-19大流行的出现。可能导致市场增长的其他因素包括血液癌和骨髓移植迅速崛起。

The emergence of the COVID-19 pandemic has increased the risk of developing mucormycosis. Before the pandemic, this fungal infection was rare, and the global incidence was just only 0.06 per 10,000 people every year. COVID-19 is causing huge healthcare challenges across the globe. COVID-19 was detected in more than 155 million global people as of May 2021. US, India, and Brazil are the worst affected countries due to the pandemic.

In the U.S. alone, more than 33 million people are affected by the disease till now. India is facing the worst second wave where 4, 00,000 cases are detected every day which is the highest number of cases for any country from the beginning of the pandemic. The increasing cases of COVID-19 will significantly increase the number of mucormycosis cases across the global market.

Industry Dynamics

Growth Drivers
随着Covid-19患者通过使用用于病毒治疗的某些药物，PANSIMIX具有增加的粘液霉菌病的风险增加。通常，类固醇和其他抗病毒药物用于治疗中会显着影响患者的免疫系统。类固醇治疗还将增加电晕患者的血糖水平，这将使它们变得更容易受粘性霉菌症。

印度的一些医院正在治疗200款粘性症患者，其中一些地区的马哈拉施特拉州的地区已在市场上发生大流行病的第二波粘膜病例升高100％-200％。

Mucormycosis will lead to blindness, organ dysfunctions, and other problems which may sometimes require surgical treatments. The exponential increase in cases of COVID-19 associated with mucormycosis in certain parts of the world will be the main factor for the growth of the global market during the forecast period.

The other important market factors that will contribute to the global mucormycosis market include an increase in organ and bone marrow transplantation along with growing hematological cancer cases and diabetic patients since these people will have a weak immune system.

Globally an approximated 0.45 million people are diagnosed with leukemia every year. Currently, 463 million diabetic people are living worldwide, and the numbers are expected to reach 578 million, by 2030. Hence the chances of people developing fungal infection will also increase in the coming years.

New drugs and diagnostic procedures are being introduced for the treatment and diagnosis of the infection. In September 2019, U.S. FDA granted Fast Track designations for intravenous (IV) and oral formulations for fosmanogepix (APX001) developed, by Amplyx Pharmaceuticals.

它被批准治疗七种包含粘液菌病的适应症。PFizer Inc.与其合作伙伴Basilea Pharmaceutica Ltd在2020年在台湾推出Cremba（Isavuconazole）。该药用于粘液菌病和侵袭性曲曲。

Mucormycosis Market Research Scope

The market is primarily segmented on the basis of diagnosis, treatment, end-use, and region.

By Diagnosis	通过治疗	通过最终使用	按地区
计算断层扫描（CT） 磁共振成像（MRI） 组织活检 Others	手术 抗真菌药物 两性霉素B治疗 Others	医院和诊所 医疗机构 研究组织 Others	北美（美国，加拿大） 欧洲（法国，德国，意大利，西班牙，英国，荷兰，奥地利） 亚太地区（中国，印度，日本，印度尼西亚，马来西亚，韩国） Latin America (Argentina, Brazil, Mexico) 中东和非洲(以色列、沙特阿拉伯、阿拉伯联合酋长国、South Africa)

了解有关此报告的更多信息：request for sample pages

Insight By Treatment

在治疗的基础上将市场分段为抗真菌药物，两性霉素治疗等。抗真菌药物市场部分进一步分为posaconazole，氟康唑，异戊酰唑，伏立康唑，氟氨基等。

抗真菌药物和两性霉素B治疗主要用于治疗。用于粘膜粘性症的唯一批准的抗真菌疗法是两性霉素B（AMB）制剂，其中脂质体AMB（L-AMB）通常在欧洲使用作为治疗标准。

Geographic Overview

由于Covid-19案件的增加，北美将成为粘液霉菌的最大市场，随着Covid-19案例的增加以及糖尿病人和血液癌的病例增加。几乎，3500万人受糖尿病的影响，约1,78,000人被诊断出血液学癌症。改善的医疗保健已经导致许多乐动娱乐官网移植程序，每年在美国进行近5,000个骨髓移植。

Asia Pacific is expected to be the fastest-growing market during the forecast period. The increasing case of COVID-19 has resulted in an unprecedented increase in the cases of mucormycosis in countries like India. The cases of HIV are also more in the Southeast Asian region and India with 2.1 million people is the third-worst HIV-affected country in the globe.

竞争洞察力

由于Covid-19流行的出现，公司专注于开发新的药物和方法，以诊断粘液霉病。主要市场参与者正在进入全球毒品分销的伙伴关系和合作。

一些主要的市场参与者在粘液菌等市场运营的主要市场参与者包括Biocon Limited，雅培实验室，Cadila Pharmaceuticals Limited，F. Hoffman La Roche，Novartis Ag，Merck Sharp和Dohme，Bristol Myers Squibb，Mylan Labs，Bayer Ag，Sanofi，Sanofi，Lonza集团，约翰逊和约翰逊，Gilead Sciences和Pfizer Inc.